Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

IMPORTANCE: β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease. OBJECTIVE: To perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology and clinical measures. DESIGN, SETTING, AND PARTICIPANTS: The Stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shcherbinin, Sergey, Evans, Cynthia D., Lu, Ming, Andersen, Scott W., Pontecorvo, Michael J., Willis, Brian A., Gueorguieva, Ivelina, Hauck, Paula M., Brooks, Dawn A., Mintun, Mark A., Sims, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468959/
https://www.ncbi.nlm.nih.gov/pubmed/36094645
http://dx.doi.org/10.1001/jamaneurol.2022.2793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468959/
https://www.ncbi.nlm.nih.gov/pubmed/36094645
http://dx.doi.org/10.1001/jamaneurol.2022.2793

Ejemplares similares